CA2504028A1 - Methods for the treatment, prevention and management of macular degeneration - Google Patents

Methods for the treatment, prevention and management of macular degeneration Download PDF

Info

Publication number
CA2504028A1
CA2504028A1 CA002504028A CA2504028A CA2504028A1 CA 2504028 A1 CA2504028 A1 CA 2504028A1 CA 002504028 A CA002504028 A CA 002504028A CA 2504028 A CA2504028 A CA 2504028A CA 2504028 A1 CA2504028 A1 CA 2504028A1
Authority
CA
Canada
Prior art keywords
heterocycle
alkyl
aryl
arylalkyl
nr8r9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504028A
Other languages
English (en)
French (fr)
Inventor
Jerome B. Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2504028A1 publication Critical patent/CA2504028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002504028A 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration Abandoned CA2504028A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42289602P 2002-10-31 2002-10-31
US60/422,896 2002-10-31
US10/699,105 2003-10-30
US10/699,105 US20040092568A1 (en) 2002-10-31 2003-10-30 Methods for the treatment, prevention and management of macular degeneration
PCT/US2003/034662 WO2004041191A2 (en) 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration

Publications (1)

Publication Number Publication Date
CA2504028A1 true CA2504028A1 (en) 2004-05-21

Family

ID=32233518

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504028A Abandoned CA2504028A1 (en) 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration

Country Status (11)

Country Link
US (1) US20040092568A1 (https=)
EP (1) EP1565188A2 (https=)
JP (1) JP2006507307A (https=)
KR (1) KR20050061596A (https=)
AU (1) AU2003286802A1 (https=)
BR (1) BR0315939A (https=)
CA (1) CA2504028A1 (https=)
MX (1) MXPA05004550A (https=)
NZ (1) NZ540187A (https=)
TW (1) TW200420290A (https=)
WO (1) WO2004041191A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
ES2284308B1 (es) * 2005-03-08 2008-08-01 Bsh Electrodomesticos España, S.A. Tambor para maquina lavadora de ropa.
CA2663545A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
JP5808107B2 (ja) 2008-12-17 2015-11-10 学校法人慶應義塾 細胞特異的能動集積性を有する光線力学療法剤
WO2010113753A1 (ja) * 2009-03-30 2010-10-07 参天製薬株式会社 ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
CN115784993A (zh) * 2022-11-23 2023-03-14 四川大学华西医院 一种3-氨基吲唑类化合物的制备及其治疗帕金森病的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075116A (en) * 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
KR20080028516A (ko) * 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
JP4739632B2 (ja) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto

Also Published As

Publication number Publication date
JP2006507307A (ja) 2006-03-02
NZ540187A (en) 2008-03-28
US20040092568A1 (en) 2004-05-13
TW200420290A (en) 2004-10-16
WO2004041191A3 (en) 2004-12-02
BR0315939A (pt) 2005-09-13
KR20050061596A (ko) 2005-06-22
AU2003286802A1 (en) 2004-06-07
EP1565188A2 (en) 2005-08-24
MXPA05004550A (es) 2005-07-26
WO2004041191A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
AU2003284980B2 (en) Treatment of pain with JNK inhibitors
RU2297243C2 (ru) Ингибиторы киназы-3 гликогенсинтазы (gsk-3) для лечения глаукомы
CA2504028A1 (en) Methods for the treatment, prevention and management of macular degeneration
US20060122179A1 (en) Methods and compositions using JNK inhibitors for treatment and management of central nervous system injury
CA2512056A1 (en) Drug-coated stents and methods of use therefor
JP2009519977A (ja) Ａｌｋ５調整剤を用いた眼内圧のコントロール
AU2002334635A1 (en) Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
IL126836A (en) Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases
NZ540185A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
ZA200503469B (en) Methods for the treatment, prevention and management of macular degeneration
HK1088221A (en) Methods for the treatment, prevention and management of macular degeneration
ZA200503242B (en) Treatment of pain with JNK inhibitors
MXPA06004622A (en) Cytokine inhibitory drugs for treatment of macular degeneration
HK1153935A (en) Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucomatous optic neuropathy

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20091102